Search results
Amgen touts new data for drug MariTide, moving rapidly into Phase 3 work
Endpoints News· 5 hours agoAmgen said that an interim look at a Phase 2 trial of its anti-obesity drug MariTide had left the...
Amgen Soars After CEO Gives Update on Experimental Obesity Drug
Bloomberg via Yahoo Finance· 6 hours ago(Bloomberg) -- Amgen Inc.’s shares soared in late trading after its chief executive officer said he...
...Nordisk (NYSE:NVO) and Eli Lilly (NYSE:LLY): Anti-Obesity Drug Market Could Reach Double Current...
The Wall Street Transcript· 4 days agoCiti Research Health Care Analyst Andrew Baum, M.D., maintains a “buy” recommendation on GLP-1...
Novo Nordisk Stock Falls After Pricing Pressure Mounts for Wegovy
The Wall Street Journal· 12 hours agoNovo Nordisk’s American depositary receipts slipped nearly 3%, despite reporting higher quarterly...
Wegovy & other GLP-1 drugs to get coverage under Medicare Part D
AARP· 1 day agoThe FDA recently approved a new use for Wegovy (semaglutide), the blockbuster anti-obesity drug, to reduce the risk of heart attacks ...
Why Eli Lilly's earnings are no sure thing for traders despite obesity drug momentum
CNBC· 3 days agoEli Lilly appears to be making as much of its popular obesity and diabetes medicines as it can, but...
Ozempic Breath: Can Weight Loss Drugs Cause Halitosis?
Healthline· 13 hours agoPeople can experience a range of side effects while taking GLP-1 drugs like Ozempic and Wegovy. A...
Weight-Loss Drugs Boost Case for Pharma ETFs | ETF Trends
ETF Trends· 3 days agoWeight-loss drugs, including Ozempic, are reshaping consumer habits. With help from shares of some...
Why Markets Must Beware Powell’s Comments on Fed Rate Hikes, and 5 Other Things to Know Today
Barrons.com· 16 hours agoNovo Nordisk hikes guidance as sales of weight-loss drugs surge, Qualcomm profit lifted amid high...
Goldman updates European conviction list, adds 4 new stocks By Investing.com
Investing.com· 14 hours agoGoldman updates European conviction list, adds 4 new stocks